Journal of Cardiovascular Medicine最新文献_第5页

A strange hole between the two sides of the heart. 心脏两侧之间有个奇怪的洞。

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-02 DOI: 10.2459/JCM.0000000000001730

Massimo Mapelli, Giulia Grilli, Manuela Muratori

引用次数: 0

Combined use of cardiac magnetic resonance and optical coherence tomography to unravel a MINOCA presentation. 结合使用心脏磁共振和光学相干断层扫描来揭示MINOCA的表现。

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-23 DOI: 10.2459/JCM.0000000000001743

Antonino Imbesi, Maria Sara Mauro, Maria Cristina Inserra, Davide Capodanno

引用次数: 0

Factor XI inhibitors: is it time for a paradigm shift in anticoagulation? 因子XI抑制剂：是抗凝治疗模式转变的时候了吗？

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-13 DOI: 10.2459/JCM.0000000000001735

Paolo Ossola, Claudio Ciampi, Andrea Cesari, Luca Villanova, Niccolò Grieco, Giovanna Viola, Alice Sacco, Leonardo De Luca, Fabrizio Oliva

引用次数: 0

Multidisciplinary approach and combination pharmacotherapy for the management of cardiometabolic patients. 多学科方法和联合药物治疗对心脏代谢患者的管理。

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.2459/JCM.0000000000001734

Giuseppe M C Rosano, Cristiana Vitale, Ilaria Spoletini, Kamlesh Khunti, Kostantinos Tsioufis, Sarah Onida, Marisa Papaluca, Alberto Zambon

引用次数: 0

Predictive value of scores for all-cause mortality in patients with cardiogenic shock. 心源性休克患者全因死亡率评分的预测价值。

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-01 DOI: 10.2459/JCM.0000000000001728

Domenico Simone Castiello, Alberto Polimeni, Antonio Curcio

引用次数: 0

Single vs. dual antithrombotic therapy in patients with oral anticoagulation and stabilized coronary artery disease: a systematic review and meta-analysis of randomized-controlled trials. 口服抗凝和稳定冠状动脉疾病患者的单抗与双抗血栓治疗：随机对照试验的系统回顾和荟萃分析

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-02 DOI: 10.2459/JCM.0000000000001723

Giuseppe Gargiulo, Raffaele Piccolo, Duk-Woo Park, Gi-Byoung Nam, Yasuo Okumura, Giovanni Esposito, Marco Valgimigli

{"title":"Single vs. dual antithrombotic therapy in patients with oral anticoagulation and stabilized coronary artery disease: a systematic review and meta-analysis of randomized-controlled trials.","authors":"Giuseppe Gargiulo, Raffaele Piccolo, Duk-Woo Park, Gi-Byoung Nam, Yasuo Okumura, Giovanni Esposito, Marco Valgimigli","doi":"10.2459/JCM.0000000000001723","DOIUrl":"10.2459/JCM.0000000000001723","url":null,"abstract":"Aims: Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with oral anticoagulation (OAC) and stabilized coronary artery disease (CAD) are still limited and underpowered for ischaemic events. Therefore, we investigated the safety and efficacy of single vs. dual antithrombotic therapy (SAT vs. DAT) in patients with OAC and stabilized CAD.Methods: A systematic review and meta-analysis was performed using PubMed to search for randomized clinical trials comparing SAT vs. DAT in patients with OAC and stabilized CAD.Results: Five trials encompassing 5758 patients (SAT = 2897 vs. DAT = 2861) were included. The predominant indication of OAC was atrial fibrillation (n = 5495, 95.4%). Most of the patients had prior percutaneous coronary intervention (PCI) (81.1%). The primary safety outcome (trial-defined major bleeding) was lower with SAT compared with DAT [hazard ratio 0.58, 95% confidence interval (95% CI) 0.40-0.83; P < 0.001; I2 = 65.9%] as was the composite of major bleeding or clinically relevant nonmajor (CRNM) bleeding (hazard ratio 0.62, 95% CI 0.400.96; P = 0.03; I2 = 54.6%). There were no differences between the groups in terms of all-cause death, myocardial infarction, stroke, and the trial-defined composite of major adverse cardiovascular events. These findings were consistent among sensitivity analyses.Conclusion: In OAC patients with stabilized CAD, largely due to atrial fibrillation and prior (6-12 months) PCI, SAT is associated with lower major bleeding without increased risk of ischaemic complications compared with DAT.","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 6","pages":"258-265"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral anticoagulation alone in atrial fibrillation and stable coronary artery disease: evidence silences doubt. 单独口服抗凝治疗心房颤动和稳定型冠状动脉疾病：证据沉默了怀疑。

IF 2 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-01 DOI: 10.2459/JCM.0000000000001732

Felice Gragnano, Vincenzo De Sio, Dominick J Angiolillo, Paolo Calabrò

引用次数: 0

Impact of the Killip class of heart failure on treatment times and intrahospital mortality among STEMI patients. Killip心力衰竭分级对STEMI患者治疗时间和院内死亡率的影响

IF 2.9 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-05-01 Epub Date: 2025-04-04 DOI: 10.2459/JCM.0000000000001719

Konstantinos Avranas, Marcus Mittag, Kerstin Schadow, Kerstin Eck, Ralf Lehmann

{"title":"Impact of the Killip class of heart failure on treatment times and intrahospital mortality among STEMI patients.","authors":"Konstantinos Avranas, Marcus Mittag, Kerstin Schadow, Kerstin Eck, Ralf Lehmann","doi":"10.2459/JCM.0000000000001719","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001719","url":null,"abstract":"Aims: While timely reperfusion is known to reduce mortality, the extent to which the severity of heart failure, as classified by the Killip system, influences treatment delays remains unclear. Our study aims to address the existing gap in evidence regarding the relationship between Killip classification at presentation and treatment times in ST-elevation myocardial infarction (STEMI) patients.Methods: We conducted a correlative analysis using data from patients treated in our hospital and enrolled in the FITT-STEMI Register from 2009 to 2022. We focused on the relation of treatment times allocating patients into the four Killip classes and used an ANOVA test (significance level: P < 0.05). Killip class and intrahospital mortality were studied via binary logistic regression.Results: In total, 1264 patients were identified. Door-to-balloon time among Killip I patients was 54 (±35) min (mean ± SD) and 53 (±26) min among Killip II and prolonged up to 77.5 (±46) min for class III and 79.7 (±45) min for class IV (overall P -value < 0.001). This remained statistically significant even after the exclusion of patients with out-of-hospital cardiac arrest (OHCA) (overall P -value: <0.001).Post hoc analysis showed a significant difference between Killip II and III classes for both all-comers ( P = 0.014) as well as after the exclusion of OHCA patients ( P = 0.012).Intrahospital mortality increased from <5% for classes I and II up to 10.3% for class III and 35.4% for class IV.Conclusion: The severity of heart failure among STEMI patients significantly affects the duration of treatment times. Patients presenting with Killip class III and IV demonstrate high intrahospital mortality rates.","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 5","pages":"240-247"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of vericiguat in a heart transplant recipient with biventricular dysfunction. vericiguat在双心室功能障碍心脏移植受者中的应用。

IF 2.9 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-05-01 Epub Date: 2025-04-11 DOI: 10.2459/JCM.0000000000001722

Daniele Masarone, Luigi Falco, Dario Catapano, Cristiano Amarelli, Claudio Marra, Emilio di Lorenzo

引用次数: 0

Diagnostic accuracy of ECG and N-terminal pro B-type natriuretic peptide for cardiac dysfunction among asymptomatic long-term breast cancer survivors. 心电图和n端前b型利钠肽对无症状长期乳腺癌幸存者心功能障碍的诊断准确性

IF 2.9 3区医学

Journal of Cardiovascular Medicine Pub Date : 2025-05-01 Epub Date: 2025-03-27 DOI: 10.2459/JCM.0000000000001710

Rachel Knol, Laurine T van der Wal, Jozine M Ter Maaten, Geertruida H de Bock, Saskia W M C Maass, Daan Brandenbarg

{"title":"Diagnostic accuracy of ECG and N-terminal pro B-type natriuretic peptide for cardiac dysfunction among asymptomatic long-term breast cancer survivors.","authors":"Rachel Knol, Laurine T van der Wal, Jozine M Ter Maaten, Geertruida H de Bock, Saskia W M C Maass, Daan Brandenbarg","doi":"10.2459/JCM.0000000000001710","DOIUrl":"https://doi.org/10.2459/JCM.0000000000001710","url":null,"abstract":"Background: With a growing population of breast cancer survivors, it is important to acknowledge long-term consequences of breast cancer treatment, including left ventricular systolic dysfunction (LVSD). Although echocardiography is a reliable technique to diagnose LVSD, its limited accessibility in primary care poses challenges.Methods: A cross-sectional diagnostic accuracy study among 350 long-term breast cancer survivors, at least 5 years after breast cancer diagnosis, comparing the diagnostic performance of index tests ECG and N-terminal pro B-type natriuretic peptide (NT-proBNP) to the reference test echocardiography. LVSD was defined as left ventricular ejection fraction (LVEF) less than 54% or LVEF less than 50% on echocardiography.Results: The median age at time of investigation was 63 years (IQR 57-68), with a median follow-up duration since breast cancer diagnosis of 10 years (IQR 7-14). An abnormal ECG demonstrated a sensitivity of 63.0% (IQR 48.7-75.7), a corresponding specificity of 51.7 (IQR 45.8-57.6) and a negative likelihood ratio of 0.7 (IQR 0.5-1.0) for detecting a LVEF less than 54%. An abnormal ECG showed a sensitivity of 75.0 (IQR 47.6-92.7), a corresponding specificity of 50.6 (IQR 45.1-56.2) and a negative likelihood ratio of 0.5 (0.2-1.2) for detecting LVSD defined as LVEF less than 50%. The area under the curve for NT-proBNP was 0.59 (95% confidence interval: 0.50-0.68) for detecting LVEF less than 54% and 0.56 (95% confidence interval: 0.39-0.74) for detecting LVEF less than 50%.Discussion: ECG and NT-proBNP are inadequate diagnostic tools to screen for LVSD among asymptomatic long-term breast cancer survivors.","PeriodicalId":15228,"journal":{"name":"Journal of Cardiovascular Medicine","volume":"26 5","pages":"216-223"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0